<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955097</url>
  </required_header>
  <id_info>
    <org_study_id>Definity 08.0119</org_study_id>
    <secondary_id>08.0119</secondary_id>
    <nct_id>NCT00955097</nct_id>
  </id_info>
  <brief_title>Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors</brief_title>
  <acronym>Definity®</acronym>
  <official_title>Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to demonstrate the safety and effectiveness of using an
      intra-operative ultrasound contrast agent(Definity®) for the identification of known liver
      tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to demonstrate the safety of the use of
      intra-operative ultrasound contrast (Definity®) administration. The secondary objective of
      this study is to demonstrate the improved image quality and conspicuity of known liver tumors
      using contrast enhancement.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No funding for this study
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>6-weeks post surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>identification of liver tumors</measure>
    <time_frame>intra-operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>improved ablation of liver tumors</measure>
    <time_frame>6-weeks post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Liver Tumors</condition>
  <arm_group>
    <arm_group_label>Definity Contrast Dye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During liver surgery Definity contrast dye will be administered follwed by an ultrasound to better detect liver tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Definity®</intervention_name>
    <description>Definity® injections given both pre-ablation and post-ablation</description>
    <arm_group_label>Definity Contrast Dye</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Undergoing a hepatic resection or hepatic ablation of pre-operative visualized liver
             tumor:

          2. ≥ 18 years of age

          3. If female of child-bearing potential, negative pregnancy test within 14 days prior to
             surgery

          4. If subject is a sexually active male or a sexually active female of child-bearing
             potential, subject agrees to use a medically accepted form of contraception from the
             time of enrollment to completion of all follow-up study visits.

          5. IRB-approved informed consent, signed by the subject or the subject's legally
             authorized representative. ≥ 18 years of age

        Exclusion Criteria:

        1. Not a suitable candidate for operation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norton Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2009</study_first_submitted>
  <study_first_submitted_qc>August 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2009</study_first_posted>
  <last_update_submitted>October 18, 2013</last_update_submitted>
  <last_update_submitted_qc>October 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Robert C. Martin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Definity</keyword>
  <keyword>liver tumors</keyword>
  <keyword>intra operative contrast</keyword>
  <keyword>liver cancer</keyword>
  <keyword>hepatic tumors</keyword>
  <keyword>identify liver tumors</keyword>
  <keyword>surgery liver tumors</keyword>
  <keyword>Patients with known hepatic tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

